Jim Cramer gives his take on Centene's decline and the managed care sector

Centene shares plummeted over 40% to a 52-week low after the company unexpectedly withdrew its full-year forecast and drastically cut adjusted diluted EPS guidance from $7.25 to $2.75, citing lower-than-expected market growth in most states. This severe revision, particularly impacting its government healthcare exchange business, prompted Jim Cramer to label the entire managed care industry "un-investable," warning of rising healthcare costs for insurers, potential enrollment attrition, and adverse effects from proposed Medicaid policy changes, signaling a challenging outlook for the sector.

Analysis

Centene (CNC) experienced a severe market repricing, with its stock falling over 40% to a new 52-week low, following the unexpected withdrawal of its full-year forecast. The company slashed its adjusted diluted earnings per share guidance to $2.75, a drastic reduction from the $7.25 estimated in April, citing weaker-than-expected market growth in 22 of the 29 states it serves. This negative development has significant implications beyond Centene, triggering losses across the managed care sector. The core issue appears to be a dual-sided pressure: rising healthcare costs are increasing payouts, while enrollment trends suggest potential adverse selection, where healthier individuals are leaving government-sponsored exchanges, concentrating risk among a sicker, more expensive-to-insure population. Compounding these operational challenges is a significant regulatory overhang from a proposed Senate bill, which threatens to shrink Centene's core Medicaid customer base. The combination of deteriorating company fundamentals, negative industry-wide cost trends, and acute legislative risk frames an exceptionally challenging outlook for Centene and casts a pall over the entire health insurance cohort.

Key Decisions for Investors

• Given the complete withdrawal of financial guidance and the fundamental deterioration in its core business, investors should consider avoiding or exiting positions in Centene until there is a clear and stable outlook.
• Exercise extreme caution across the entire managed care sector, as Centene's issues with rising costs and potential adverse selection could be symptomatic of broader industry headwinds.
• Closely monitor legislative developments related to U.S. healthcare policy and watch for earnings pre-announcements from Centene's peers, as these will be key catalysts for further volatility in the sector.